# Notice of Intent - Sole Source for Pluvicto

Canonical: https://abierto.us/opportunities/36c25225f0191

- Solicitation number: 36C25225F0191
- Notice type: Special notice
- Status: Awarded to Novartis Pharmaceuticals Corporation
- Department: Department of Veterans Affairs
- Contracting office: 252-Network Contract Office 12 (36C252)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- County: Morris County (FIPS 34027). https://abierto.us/counties/morris-county-nj-34027
- First posted: August 19, 2025
- Last posted: August 19, 2025
- SAM.gov: https://sam.gov/workspace/contract/opp/f825d9b28ccb45e79941db19db1b393f/view

## Description

The Department of Veterans Affairs, VHA Regional Procurement Office Central, Great Lakes Acquisition Center, Network Contracting Office 12, located at 115 S. 84th Street, Suite 101, Milwaukee, WI 53214-1476 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan).

The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical.

Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation.

This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Parris.Weidenbach@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement.

This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to Parris.Weidenbach@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.

## Award on USAspending

- Recipient: Novartis Pharmaceuticals Corporation (UEI NG61ZA8TADW3)
- Contract: 36C25225F0191 under 36F79720D0180, delivery order
- Obligated: $1,733,030.46
- Competition: Full and Open Competition, 1 offers received
- Link: solicitation number 36C25225F0191 was reused as the contract number; same awarding office 36C252 (high confidence)
- Record: https://www.usaspending.gov/award/CONT_AWD_36C25225F0191_3600_36F79720D0180_3600/


## Publications

- August 19, 2025: Special notice, due August 26, 2025 at 5:00 PM EDT. Notice f825d9b28ccb45e79941db19db1b393f. https://sam.gov/workspace/contract/opp/f825d9b28ccb45e79941db19db1b393f/view

## Points of contact

- Parris S Weidenbach, Contract Specialist, parris.weidenbach@va.gov, 414-844-4895

---
Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/36c25225f0191.